Evaluation of Cellular Toxicity and Preclinical Safety of Using an Inhalable Liposomal form of Dexamethasone.

A liposomal form of dexamethasone was obtained. Liposomal vesicles were formed. The efficiency of incorporating dexamethasone into the liposomes was 99.

Design of Nanosomal Form of Aprotinin.

Liposomes containing aprotinin were produced by the phase inversion technique and purified by gel filtration. Aprotinin inclusion was assessed fluorescence labeling of the protein. The size of obtained liposomes was 212±35 nm and aprotinin concentration in the liposomal suspension was 3000 KIU/ml.